September 29, 2017 / 2:20 PM / in 23 days

BRIEF-Novo Nordisk's fast-acting mealtime insulin Fiasp approved in the U.S.

Sept 29 (Reuters) - NOVO NORDISK SAYS

* THE UNITED STATES’ FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED FIASP (FAST-ACTING INSULIN ASPART), A NEW FAST-ACTING MEALTIME INSULIN, FOR TREATMENT OF ADULTS WITH DIABETES

* FDA‘S DECISION COMES AFTER FIASP IN CLINICAL TRIALS DEMONSTRATED BENEFITS FOR PEOPLE IN NEED OF IMPROVED OVERALL GLUCOSE CONTROL

* IN CLINICAL TRIALS FIASP HAS DEMONSTRATED CLINICALLY RELEVANT IMPROVEMENT IN LONG-TERM GLUCOSE LEVEL Source text for Eikon: Further company coverage: (Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below